CDR-Life has announced new developments to its programme of antibody-based T cell engagers (TCE) targeting intracellular tumour antigens MAGE-A4 and PRAME via the major histocompatibility complex. The first patient has been dosed with CDR404, a novel, bispecific and bivalent antibody fragment-based TCE targeting MAGE-A4. Read More
The European Society for Medical Oncology (ESMO) Congress 2024 took place in Barcelona, Spain, 13-17 September 2024, and featured some significant breakthroughs in cancer drug discovery. NIAGARA Phase III trial AstraZeneca presented positive results from its NIAGARA Phase III trial, a global study to evaluate the… Read More
Janssen-Cilag has shared new data from the Phase Ib/II OrigAMI-1 study at the European Society of Medical Oncology (ESMO) 2024 Congress. The results show that amivantamab combined with chemotherapy demonstrated promising antitumour activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not… Read More
A new study has demonstrated that the frequency of second primary malignancies (SPMs) is no higher with CAR-T cell therapies than with previous standard-of-care strategies. The authors found that T cell malignancies represented a small minority of adverse events at just 1.5%. The paper ‘… Read More
Oxford Nanopore Technologies has joined the PROGRESS study to support improved outcomes for childhood leukaemias in Ghana. The consortium so far includes Yemaachi Biotech, Pediatric Oncology Units at Korle Bu Teaching Hospital, Komfo Anokye Teaching Hospital and Greater Accra Regional Hospital, and institutions like Newcastle University,… Read More
With an initial investment of £28 million in resources and funding, LifeArc and Cancer Research UK have launched a new initiative to develop medicines exclusively for children’s and young people’s cancers. C-Further will bring together researchers, clinicians, scientists and industry to provide support, finance and expertise. Read More
Boehringer Ingelheim has reported positive results from its Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. Zongertinib, an investigational oral HER2 tyrosine kinase inhibitor… Read More
Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma (DHG), new research has found. A team of scientists from The Institute of Cancer Research, London and the Dana-Farber Cancer Institute, Boston, USA, have uncovered clues… Read More
The Phase II NANOBRAINMETS trial of AGuIX has been validated by the Data Safety and Monitoring Board (DSMB) following a futility analysis scheduled after the enrolment and follow-up of 50% of patients in the study. The trial is being run by NH TherAguix, a biotechnology company developing… Read More
Researchers from Flinders University and University of South Australia have unveiled a promising new strategy that could be used to treat the most aggressive forms of prostate cancer. This study, published in British Journal of Cancer, explores the role of a novel drug, CDKI-73, to tackle… Read More
Grit Biotechnology has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) for its genetically engineered tumour-infiltrating lymphocyte (TIL) product GT201. The therapy is now approved by both the FDA and China Center for Drug Evaluation (CDE) to enter clinical trials in both countries for… Read More
Twenty-three companies will benefit from a share of £12 ($15.8) million from the Innovate UK Cancer Therapeutics programme. The Cancer Therapeutics programme focuses on developing life-changing cancer treatments, including immunotherapies and vaccines. It also supports projects addressing unmet medical needs for treating childhood and young persons’ cancers. The investment from… Read More
Dr Nicholas Siciliano, Co-Founder of Vittoria Biotherapeutics, shares insight on the VIPER-101 trial targeting T-cell lymphoma, the company’s aim to ensure progression free survival and opportunities in this sector. MT: I understand that your lead programme is moving into the clinic, with POC human data expected in 2024. Can you… Read More
A lung cancer patient at University College London Hospitals (UCLH) is the first to receive a novel cancer vaccine designed to prime the immune system to recognise and fight cancer cells. It is the first time this immunotherapy made by BioNTech will be studied in a clinical… Read More
Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02. TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer,… Read More
Phanes Therapeutics' PT217 has received orphan drug designation (ODD) for neuroendocrine carcinoma (NEC) from the US Food and Drug Administration (FDA). PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC. NEC is known to be the… Read More
